Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 55 entries
Sorted by: Best Match Show Resources per page
Effects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency.

Therapeutic advances in endocrinology and metabolism

Ramiro-Lozano JM, Calvo-Romero JM.
PMID: 26623001
Ther Adv Endocrinol Metab. 2015 Dec;6(6):245-8. doi: 10.1177/2042018815599874.

BACKGROUND: Epidemiological studies suggest that vitamin D status may have an influence on lipid profile.PATIENTS AND METHODS: We studied consecutive type 2 diabetic patients with vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) lower than 20 ng/ml). They were treated...

Cite
Ramiro-Lozano JM, Calvo-Romero JM. Effects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency. Ther Adv Endocrinol Metab. 2015;6(6):245-8doi: 10.1177/2042018815599874.
Ramiro-Lozano, J. M., & Calvo-Romero, J. M. (2015). Effects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency. Therapeutic advances in endocrinology and metabolism, 6(6), 245-8. https://doi.org/10.1177/2042018815599874
Ramiro-Lozano, José Manuel, and Calvo-Romero, José María. "Effects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency." Therapeutic advances in endocrinology and metabolism vol. 6,6 (2015): 245-8. doi: https://doi.org/10.1177/2042018815599874
Ramiro-Lozano JM, Calvo-Romero JM. Effects on lipid profile of supplementation with vitamin D in type 2 diabetic patients with vitamin D deficiency. Ther Adv Endocrinol Metab. 2015 Dec;6(6):245-8. doi: 10.1177/2042018815599874. PMID: 26623001; PMCID: PMC4647130.
Copy Download .nbib Format: NLM
Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report.

International journal of nephrology and renovascular disease

Cupisti A, Vigo V, Baronti ME, D'Alessandro C, Ghiadoni L, Egidi MF.
PMID: 26640388
Int J Nephrol Renovasc Dis. 2015 Nov 19;8:151-7. doi: 10.2147/IJNRD.S90968. eCollection 2015.

This study investigated the factors associated with hypovitaminosis D, in a cohort of 405 prevalent patients with chronic kidney disease (CKD) stages 2-4, living in Italy and followed-up in tertiary care. The effect of cholecalciferol 10,000 IU once-a-week for...

Cite
Cupisti A, Vigo V, Baronti ME, et al. Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report. Int J Nephrol Renovasc Dis. 2015;8:151-7doi: 10.2147/IJNRD.S90968.
Cupisti, A., Vigo, V., Baronti, M. E., D'Alessandro, C., Ghiadoni, L., & Egidi, M. F. (2015). Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report. International journal of nephrology and renovascular disease, 8151-7. https://doi.org/10.2147/IJNRD.S90968
Cupisti, Adamasco, et al. "Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report." International journal of nephrology and renovascular disease vol. 8 (2015): 151-7. doi: https://doi.org/10.2147/IJNRD.S90968
Cupisti A, Vigo V, Baronti ME, D'Alessandro C, Ghiadoni L, Egidi MF. Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report. Int J Nephrol Renovasc Dis. 2015 Nov 19;8:151-7. doi: 10.2147/IJNRD.S90968. eCollection 2015. PMID: 26640388; PMCID: PMC4657801.
Copy Download .nbib Format: NLM
Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study.

Reports of biochemistry & molecular biology

Javanbakht MH, Mohammady H, Fooladsaz K, Razzaghi M, Zarei M, Djalali M.
PMID: 28070531
Rep Biochem Mol Biol. 2016 Oct;5(1):26-32.

BACKGROUND: Considerable evidence suggests that oxidative stress affects diabetes mellitus (DM) and contributes to its complications. Vitamin D has been shown to possess antioxidant properties. The aim of this study was to determine the association between serum levels of...

Cite
Javanbakht MH, Mohammady H, Fooladsaz K, et al. Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study. Rep Biochem Mol Biol. 2016;5(1):26-32
Javanbakht, M. H., Mohammady, H., Fooladsaz, K., Razzaghi, M., Zarei, M., & Djalali, M. (2016). Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study. Reports of biochemistry & molecular biology, 5(1), 26-32.
Javanbakht, Mohammad Hassan, et al. "Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study." Reports of biochemistry & molecular biology vol. 5,1 (2016): 26-32.
Javanbakht MH, Mohammady H, Fooladsaz K, Razzaghi M, Zarei M, Djalali M. Are Serum Levels of F2-Isoprostane and Oxidized-LDL Related to Vitamin D Status in Type 2 Diabetic Patients? A Case-Control Study. Rep Biochem Mol Biol. 2016 Oct;5(1):26-32. PMID: 28070531; PMCID: PMC5214680.
Copy Download .nbib Format: NLM
Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

Expert review of endocrinology & metabolism

Sprague SM, Strugnell SA, Bishop CW.
PMID: 30058895
Expert Rev Endocrinol Metab. 2017 Sep;12(5):289-301. doi: 10.1080/17446651.2017.1347501. Epub 2017 Jul 11.

INTRODUCTION: Extended-release calcifediol (ERC) 30 µg capsules were recently approved as Rayaldee® by the United States Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3-4 (not 5) chronic kidney disease (CKD)...

Cite
Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017;12(5):289-301doi: 10.1080/17446651.2017.1347501.
Sprague, S. M., Strugnell, S. A., & Bishop, C. W. (2017). Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert review of endocrinology & metabolism, 12(5), 289-301. https://doi.org/10.1080/17446651.2017.1347501
Sprague, Stuart M, et al. "Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease." Expert review of endocrinology & metabolism vol. 12,5 (2017): 289-301. doi: https://doi.org/10.1080/17446651.2017.1347501
Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017 Sep;12(5):289-301. doi: 10.1080/17446651.2017.1347501. Epub 2017 Jul 11. PMID: 30058895.
Copy Download .nbib Format: NLM
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol.

American journal of nephrology

Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, Bishop CW, Ashfaq A.
PMID: 34818216
Am J Nephrol. 2021;52(10):798-807. doi: 10.1159/000518545. Epub 2021 Oct 27.

INTRODUCTION: The safety and efficacy of extended-release calcifediol (ERC) as a treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI) has been demonstrated in prospective randomized clinical...

Cite
Fadda G, Germain MJ, Broumand V, et al. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. Am J Nephrol. 2021;52(10):798-807doi: 10.1159/000518545.
Fadda, G., Germain, M. J., Broumand, V., Nguyen, A., McGarvey, N., Gitlin, M., Bishop, C. W., & Ashfaq, A. (2021). Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. American journal of nephrology, 52(10), 798-807. https://doi.org/10.1159/000518545
Fadda, George, et al. "Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol." American journal of nephrology vol. 52,10 (2021): 798-807. doi: https://doi.org/10.1159/000518545
Fadda G, Germain MJ, Broumand V, Nguyen A, McGarvey N, Gitlin M, Bishop CW, Ashfaq A. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. Am J Nephrol. 2021;52(10):798-807. doi: 10.1159/000518545. Epub 2021 Oct 27. PMID: 34818216.
Copy Download .nbib Format: NLM
Vitamin D Endocrine System and COVID-19.

JBMR plus

Bouillon R, Quesada-Gomez JM.
PMID: 34950831
JBMR Plus. 2021 Nov 17;5(12):e10576. doi: 10.1002/jbm4.10576. eCollection 2021 Dec.

Preclinical data strongly suggest that the vitamin D endocrine system (VDES) may have extraskeletal effects. Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion...

Cite
Bouillon R, Quesada-Gomez JM. Vitamin D Endocrine System and COVID-19. JBMR Plus. 2021;5(12):e10576doi: 10.1002/jbm4.10576.
Bouillon, R., & Quesada-Gomez, J. M. (2021). Vitamin D Endocrine System and COVID-19. JBMR plus, 5(12), e10576. https://doi.org/10.1002/jbm4.10576
Bouillon, Roger, and Quesada-Gomez, José Manuel. "Vitamin D Endocrine System and COVID-19." JBMR plus vol. 5,12 (2021): e10576. doi: https://doi.org/10.1002/jbm4.10576
Bouillon R, Quesada-Gomez JM. Vitamin D Endocrine System and COVID-19. JBMR Plus. 2021 Nov 17;5(12):e10576. doi: 10.1002/jbm4.10576. eCollection 2021 Dec. PMID: 34950831; PMCID: PMC8674769.
Copy Download .nbib Format: NLM
Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer.

Veterinary and comparative oncology

Weidner N, Mutsaers AJ, Woods JP, Wood GA, Bayle J, Verbrugghe A.
PMID: 33222403
Vet Comp Oncol. 2021 Jun;19(2):232-241. doi: 10.1111/vco.12667. Epub 2021 Jan 14.

Decreased circulating 25-hydroxyvitamin D (25[OH]D) and increased inflammatory marker concentrations have been reported separately in canine cancer. Correlations between the two exist in humans, but little work has examined links in dogs. This study aimed to determine plasma 25(OH)D...

Cite
Weidner N, Mutsaers AJ, Woods JP, et al. Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer. Vet Comp Oncol. 2021;19(2):232-241doi: 10.1111/vco.12667.
Weidner, N., Mutsaers, A. J., Woods, J. P., Wood, G. A., Bayle, J., & Verbrugghe, A. (2021). Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer. Veterinary and comparative oncology, 19(2), 232-241. https://doi.org/10.1111/vco.12667
Weidner, Nicole, et al. "Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer." Veterinary and comparative oncology vol. 19,2 (2021): 232-241. doi: https://doi.org/10.1111/vco.12667
Weidner N, Mutsaers AJ, Woods JP, Wood GA, Bayle J, Verbrugghe A. Plasma 25-hydroxyvitamin D and the inflammatory response in canine cancer. Vet Comp Oncol. 2021 Jun;19(2):232-241. doi: 10.1111/vco.12667. Epub 2021 Jan 14. PMID: 33222403.
Copy Download .nbib Format: NLM
Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity.

Dysphagia

Bravo-José P, Sáez-LLeó C, Moreno-Guillamont E.
PMID: 34373976
Dysphagia. 2021 Aug 09; doi: 10.1007/s00455-021-10348-7. Epub 2021 Aug 09.

Older adults with oropharyngeal dysphagia (OD) are unable to swallow pills safely, so some of them use liquid-formulated drugs mixed with thickeners to ensure safety. The aim of this study was to analyze the physical compatibility of a group...

Cite
Bravo-José P, Sáez-LLeó C, Moreno-Guillamont E. Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity. Dysphagia. 2021;doi: 10.1007/s00455-021-10348-7.
Bravo-José, P., Sáez-LLeó, C., & Moreno-Guillamont, E. (2021). Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity. Dysphagia, . https://doi.org/10.1007/s00455-021-10348-7
Bravo-José, Patricia, et al. "Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity." Dysphagia vol. (2021). doi: https://doi.org/10.1007/s00455-021-10348-7
Bravo-José P, Sáez-LLeó C, Moreno-Guillamont E. Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity. Dysphagia. 2021 Aug 09; doi: 10.1007/s00455-021-10348-7. Epub 2021 Aug 09. PMID: 34373976.
Copy Download .nbib Format: NLM
Evaluation of vitamin D relationship with type 2 diabetes and systolic blood pressure.

BMJ open diabetes research & care

Nayak SB, Ramnanansingh TG.
PMID: 27843555
BMJ Open Diabetes Res Care. 2016 Oct 10;4(1):e000285. doi: 10.1136/bmjdrc-2016-000285. eCollection 2016.

OBJECTIVE: To investigate whether relationships exist among vitamin D, type 2 diabetes mellitus (T2DM), and blood pressure in Trinidadian subjects with T2DM.RESEARCH DESIGN AND METHODS: This was a case-controlled study to determine if vitamin D levels were lower in...

Cite
Nayak SB, Ramnanansingh TG. Evaluation of vitamin D relationship with type 2 diabetes and systolic blood pressure. BMJ Open Diabetes Res Care. 2016;4(1):e000285doi: 10.1136/bmjdrc-2016-000285.
Nayak, S. B., & Ramnanansingh, T. G. (2016). Evaluation of vitamin D relationship with type 2 diabetes and systolic blood pressure. BMJ open diabetes research & care, 4(1), e000285. https://doi.org/10.1136/bmjdrc-2016-000285
Nayak, Shivananda Bijoor, and Ramnanansingh, Terry Gavaskar. "Evaluation of vitamin D relationship with type 2 diabetes and systolic blood pressure." BMJ open diabetes research & care vol. 4,1 (2016): e000285. doi: https://doi.org/10.1136/bmjdrc-2016-000285
Nayak SB, Ramnanansingh TG. Evaluation of vitamin D relationship with type 2 diabetes and systolic blood pressure. BMJ Open Diabetes Res Care. 2016 Oct 10;4(1):e000285. doi: 10.1136/bmjdrc-2016-000285. eCollection 2016. PMID: 27843555; PMCID: PMC5073486.
Copy Download .nbib Format: NLM
Vitamin D status in relation to age, bone mineral density of the spine and femur in obese Saudi females - A hospital-based study.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Albrahim TI, Binobead MA.
PMID: 30766430
Saudi Pharm J. 2019 Feb;27(2):200-207. doi: 10.1016/j.jsps.2018.10.004. Epub 2018 Oct 17.

The aim of the present study was to evaluate the association between Bone mineral density in lumber spine and femoral neck with serum total levels of vitamin D, sun exposure and Consumption of vitamin D Supplement in obese Saudi...

Cite
Albrahim TI, Binobead MA. Vitamin D status in relation to age, bone mineral density of the spine and femur in obese Saudi females - A hospital-based study. Saudi Pharm J. 2018;27(2):200-207doi: 10.1016/j.jsps.2018.10.004.
Albrahim, T. I., & Binobead, M. A. (2019). Vitamin D status in relation to age, bone mineral density of the spine and femur in obese Saudi females - A hospital-based study. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 27(2), 200-207. https://doi.org/10.1016/j.jsps.2018.10.004
Albrahim, Tarfa Ibrahim, and Binobead, Manal Abdulaziz. "Vitamin D status in relation to age, bone mineral density of the spine and femur in obese Saudi females - A hospital-based study." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 27,2 (2019): 200-207. doi: https://doi.org/10.1016/j.jsps.2018.10.004
Albrahim TI, Binobead MA. Vitamin D status in relation to age, bone mineral density of the spine and femur in obese Saudi females - A hospital-based study. Saudi Pharm J. 2019 Feb;27(2):200-207. doi: 10.1016/j.jsps.2018.10.004. Epub 2018 Oct 17. PMID: 30766430; PMCID: PMC6362274.
Copy Download .nbib Format: NLM
Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1.

ISRN gastroenterology

Teichmann J, Riemann JF, Lange U.
PMID: 22111014
ISRN Gastroenterol. 2011;2011:951686. doi: 10.5402/2011/951686. Epub 2011 Nov 03.

Background. Previous research on the combined association of 25-hydroxyvitamin D [25(OH)D] and exocrine pancreas insufficiency may have been limited by restricted age variability and a lack of representation of both body weight and body mass index. There are still...

Cite
Teichmann J, Riemann JF, Lange U. Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1. ISRN Gastroenterol. 2011;2011:951686doi: 10.5402/2011/951686.
Teichmann, J., Riemann, J. F., & Lange, U. (2011). Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1. ISRN gastroenterology, 2011951686. https://doi.org/10.5402/2011/951686
Teichmann, J, et al. "Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1." ISRN gastroenterology vol. 2011 (2011): 951686. doi: https://doi.org/10.5402/2011/951686
Teichmann J, Riemann JF, Lange U. Prevalence of exocrine pancreatic insufficiency in women with obesity syndrome: assessment by pancreatic fecal elastase 1. ISRN Gastroenterol. 2011;2011:951686. doi: 10.5402/2011/951686. Epub 2011 Nov 03. PMID: 22111014; PMCID: PMC3216381.
Copy Download .nbib Format: NLM
Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?.

BBA clinical

Pasquali M, Tartaglione L, Rotondi S, Muci ML, Mandanici G, Farcomeni A, Marangella M, Mazzaferro S.
PMID: 26676064
BBA Clin. 2015 Mar 14;3:251-6. doi: 10.1016/j.bbacli.2015.03.004. eCollection 2015 Jun.

BACKGROUND: Calcifediol (25D) availability is crucial for calcitriol (1,25D) synthesis, but regulation of vitamin D hydroxylases is majorly responsible for 1,25D synthesis. The net efficiency of vitamin D hydroxylases might be informative. We assume that the ratio between calcitriol...

Cite
Pasquali M, Tartaglione L, Rotondi S, et al. Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?. BBA Clin. 2015;3:251-6doi: 10.1016/j.bbacli.2015.03.004.
Pasquali, M., Tartaglione, L., Rotondi, S., Muci, M. L., Mandanici, G., Farcomeni, A., Marangella, M., & Mazzaferro, S. (2015). Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?. BBA clinical, 3251-6. https://doi.org/10.1016/j.bbacli.2015.03.004
Pasquali, Marzia, et al. "Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?." BBA clinical vol. 3 (2015): 251-6. doi: https://doi.org/10.1016/j.bbacli.2015.03.004
Pasquali M, Tartaglione L, Rotondi S, Muci ML, Mandanici G, Farcomeni A, Marangella M, Mazzaferro S. Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?. BBA Clin. 2015 Mar 14;3:251-6. doi: 10.1016/j.bbacli.2015.03.004. eCollection 2015 Jun. PMID: 26676064; PMCID: PMC4661572.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 55 entries